PDF herunterladen
Thromb Haemost 2000; 83(03): 387-391
DOI: 10.1055/s-0037-1613824
Review Article
Schattauer GmbH

Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A

D.H. Lee
1   From the Departments of Medicine and Pathology, Queen’s University, Kingston
,
I.R. Walker
2   Departments of Medicine and Pathology, McMaster University, Hamilton
3   Canadian Hemophilia Centres
,
J. Teitel
3   Canadian Hemophilia Centres
,
M.-C. Poon
3   Canadian Hemophilia Centres
4   Departments of Medicine, Pediatrics, Oncology, and Biochemistry and Molecular Biology, University of Calgary, Canada
,
B. Ritchie
3   Canadian Hemophilia Centres
,
J. Akabutu
3   Canadian Hemophilia Centres
,
G. D. Sinclair
3   Canadian Hemophilia Centres
4   Departments of Medicine, Pediatrics, Oncology, and Biochemistry and Molecular Biology, University of Calgary, Canada
,
M. Pai
3   Canadian Hemophilia Centres
,
J. W. Y. Wu
3   Canadian Hemophilia Centres
,
S. Reddy
3   Canadian Hemophilia Centres
,
C. Carter
3   Canadian Hemophilia Centres
,
G. Growe
3   Canadian Hemophilia Centres
,
D. Lillicrap
1   From the Departments of Medicine and Pathology, Queen’s University, Kingston
3   Canadian Hemophilia Centres
,
M. Lam
1   From the Departments of Medicine and Pathology, Queen’s University, Kingston
,
M. A. Blajchman
2   Departments of Medicine and Pathology, McMaster University, Hamilton
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 12. Oktober 1998

Accepted after resubmission 12. Oktober 1999

Publikationsdatum:
14. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

To determine whether the factor V Leiden mutation is associated with decreased bleeding in individuals with severe hemophilia A, factor concentrate utilization, maximum annual number of bleeding episodes, and the prevalence of hemophilic arthropathy between carriers and non-carriers of the factor V Leiden mutation were compared. Heterozygosity for the factor V Leiden mutation was found in 6 of 137 subjects (4.4%). Carriers of the factor V Leiden mutation utilized less factor concentrate (geometric mean: 310 vs. 1185 units/kg/year) and had fewer bleeding episodes than non-carriers (proportion with 10 or fewer bleeding episodes in their worst year: 50 vs. 11%). However, the factor V Leiden mutation was not associated with the absence of arthropathy. The intron 22 inversion mutation of the factor VIII gene was tested for in a subgroup of 80 subjects, but it was not found to be a significant variable for any of the bleeding endpoints. The results of this small study are consistent with the hypothesis that the factor V Leiden mutation imparts a protective effect; however, a larger confirmatory study in which the factor VIII molecular defects can be controlled for is needed. Furthermore, most severe hemophiliacs who used fewer than 200 units/kg/year of factor concentrate or who had experienced 10 or fewer bleeding episodes per year did not carry the factor V Leiden mutation, suggesting that the proportion of severe hemophiliacs whose mild clinical course can be attributed to the factor V Leiden mutation is small.

Keywords

Factor V Leiden - hemophilia A - bleeding
 

  • References

  • 1 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
    CrossrefPubMedSuche in Google Scholar
  • 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedSuche in Google Scholar
  • 3 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
    CrossrefPubMedSuche in Google Scholar
  • 4 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
    CrossrefPubMedSuche in Google Scholar
  • 5 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
    CrossrefPubMedSuche in Google Scholar
  • 6 Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996; 155: 285-9.
    PubMedSuche in Google Scholar
  • 7 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 322: 912-7.
    PubMedSuche in Google Scholar
  • 8 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q . J Biol Chem 1995; 270: 4053-7.
    CrossrefPubMedSuche in Google Scholar
  • 9 Heeb MJ, Kojima Y, Greengard J, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
    PubMedSuche in Google Scholar
  • 10 Kalafatis M, Lu D, Bertina RM, Long GL, Mann KG. Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Arterioscl Thromb Vasc Biol 1995; 15: 2181-7.
    CrossrefPubMedSuche in Google Scholar
  • 11 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedSuche in Google Scholar
  • 12 Sinclair G, Low S, Poon M-C. A heminested allele-specific whole blood PCR assay for the detection of factor V Leiden mutation associated with activated protein C resistance. Thromb Haemost 1997; 77: 1154-5.
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Lakich D, Kazazian HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nature Genet 1993; 05: 236-41.
    CrossrefPubMedSuche in Google Scholar
  • 14 Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian HH, Negrier C, Vinciguerra C. et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
    PubMedSuche in Google Scholar
  • 15 Poon MC, Low S, Sinclair GD. Factor VIII gene rearrangement analysis and carrier determination in hemophilia A. J Lab Clin Med 1995; 125: 402-6.
    PubMedSuche in Google Scholar
  • 16 Windsor S, Taylor SAM, Lillicrap D. Direct detection of the common inversion mutation in the genetic diagnosis of severe hemophilia A. Blood 1994; 84: 2202-5.
    PubMedSuche in Google Scholar
  • 17 van’t Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor VLEIDEN. Blood 1997; 90: 3067-72.
    CrossrefPubMedSuche in Google Scholar
  • 18 Nichols WC, Amano K, Cacheris PM, Figuerido MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsberg D. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
    PubMedSuche in Google Scholar
  • 19 Lindvist PG, Svensson PJ, Dahlbäck B, Marsˇál K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss – a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
    Thieme ConnectPubMedSuche in Google Scholar
  • 20 Arruda VR, Annichino-Bizzachi JM, Antunes SV, Costa FF. Association of severe hemophilia A and factor V Leiden: report of three cases. Haemophilia 1996; 02: 51-3.
    CrossrefPubMedSuche in Google Scholar
  • 21 Chan J, Weinman AF, Thompson AR. Factor V Arg/Gln 506 has no dominant influence on the severity of hemophilia when inherited concurrently (abstract). Thromb Haemost 1995; 73 (Suppl. 01) 1793a.
    PubMedSuche in Google Scholar
  • 22 Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among “severe” hemophiliacs with a “milder” bleeding diathesis. Thromb Haemost 1995; 75: 1255-8.
    Thieme ConnectPubMedSuche in Google Scholar
  • 23 Oldenburg J, Schröder J, Schmitt C, Brackmann HH, Schwaab R. Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe hemophilia phenotype. Thromb Haemost 1998; 79: 452-3.
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Pettersson H, Gilbert M. Musculoskeletal and other haemorrhagic complications. In: Diagnostic Imaging in Hemophilia. Berlin: Springer-Verlag; 1985: 55-60.
    Suche in Google Scholar